- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1590-3478
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients ; day:26 ; month:5 ; year:2022 ; pages:1-2
Neurological sciences ; (26.5.2022), 1-2
- Creator
-
Schiano di Cola, Francesca
Caratozzolo, Salvatore
Bolchini, Marco
Ceccardi, Giulia
Cortinovis, Matteo
Liberini, Paolo
Padovani, Alessandro
Rao, Renata
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10072-022-06154-0
- URN
-
urn:nbn:de:101:1-2022072822243729309278
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Schiano di Cola, Francesca
- Caratozzolo, Salvatore
- Bolchini, Marco
- Ceccardi, Giulia
- Cortinovis, Matteo
- Liberini, Paolo
- Padovani, Alessandro
- Rao, Renata
- SpringerLink (Online service)
Other Objects (12)
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
CGRP and migraine: neurogenic inflammation revisited
Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy
Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
CGRP and migraine: neurogenic inflammation revisited
Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy
Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Monoclonal Antibodies Targeting CGRP to Treat Vestibular Migraine: A Rapid Systematic Review and Meta-Analysis
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
CGRP and migraine: neurogenic inflammation revisited
Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy
Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study